Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

Novel Therapy for Aggressive Cutaneous T-Cell Lymphoma Leading to Complete Clinical Remission before Allogenic Stem Cell Transplantation

Nicolas Gallastegui Crestani, MD, Mohammed E. Ibrahim, CRPH, BCOP, BCPS, BCACP, Ayman M. Mohamed, PharmD, Paolo Romanelli, MD, Amer Beitinjaneh, MD MPH, MSc, Jonathan H. Schatz, MD

Blood (2018) 132 (Supplement 1): 5354.

https://doi.org/10.1182/blood-2018-99-117079

Published: 2018

Journal Articles

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Brian R. Curtis, PhDMT(ASCP), Yen-Michael S. Hsu, MD PhD, Nikolai A. Podoltsev, MD PhD, Jill Lacy, MD, Susanna A Curtis, MD, Robert Andrew Desimone, MD, Michael Samuel, MD, Kristin Zutavern, BS, Daniel Bougie, PhD, Richard H. Aster, MD

Blood (2017) 130 (Supplement 1): 3625.

https://doi.org/10.1182/blood.V130.Suppl_1.3625.3625

Published: 2017

Journal Articles

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Sikander Ailawadhi, Abdel-Ghani Azzouqa, Zahara Meghji, Tania Jain, MD, Nancy Diehl, Stephanie P. Gebhardt, Vishal Shah, David O. Hodge, MS, Raj Patel, MD, Prachi Jani, MD, Taimur Sher, MD, Vivek Roy, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Rafael Fonseca, MD

Blood (2017) 130 (Supplement 1): 5440.

https://doi.org/10.1182/blood.V130.Suppl_1.5440.5440

Published: 2017

Journal Articles

Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy

Semjon Willier, MD, Karin Melanie Cabanillas Stanchi, MSc, Martha von Have, Dr. MD, Vera Binder, Dr. MD, Franziska Blaeschke, Dr. MD, Tobias F. Feuchtinger, Prof. Dr. MD, Michaela Döring, Dr. MD

Blood (2017) 130 (Supplement 1): 3220.

https://doi.org/10.1182/blood.V130.Suppl_1.3220.3220

Published: 2017

Journal Articles

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Hongtao Liu, MD PhD, Andrew Artz, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, Wendy Stock, MD, Michael R. Bishop, MD

Blood (2017) 130 (Supplement 1): 3312.

https://doi.org/10.1182/blood.V130.Suppl_1.3312.3312

Published: 2017

Journal Articles

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Salli Fennessey, Anthony C Shelton, RN

Blood (2017) 130 (Supplement 1): 507.

https://doi.org/10.1182/blood.V130.Suppl_1.507.507

Published: 2017

Journal Articles

a Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells

Guillermo J. Ruiz-Arguelles, MD FRCP (Glasg), MACP, Andrés A. León-Peña, MD, Mónica León-Gonzalez, MD, Ana Karen Núñez-Cortés, MD, Merari Starlight Torres-Priego, MD, Jocelyn Vargas-Espinosa, MD, Emilio Medina-Ceballos, MD, Alejandro Ruiz-Arguelles, MD, Manuel Alejandro Ruiz-Delgado, MBA, Rodrigo J Ruiz-Delgado, BA, Guillermo Ruiz-Reyes, MD, Manuel Priesca-Marin, MD, David Blumenkron-Marroquin, MD, Guillermo J Ruiz-Delgado, MD FACP

Blood (2016) 128 (22): 2262.

https://doi.org/10.1182/blood.V128.22.2262.2262

Published: 2016

Journal Articles

A Prospective Study of IV Pentamidine for Pneumocystis Jirovecii Pneumonia Prophylaxis in Adult Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplant or Chemotherapy

Jennifer Anderson, PharmD, Scott Wirth, PharmD, Pritesh R. Patel, MD, John G. Quigley, MD, Annie L. Oh, MD, Christina Mactal-Haaf, PharmD, Irum Khan, MD, Damiano Rondelli, MD, Karen Sweiss, PharmD

Blood (2016) 128 (22): 2207.

https://doi.org/10.1182/blood.V128.22.2207.2207

Published: 2016

Journal Articles

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

Ajai Chari, MD, Hearn Jay Cho, MD PhD, Samir Parekh, MD, Keren Osman, MD, Talia Goldstein, BA, Gillian Morgan, Lisa La, MS/CCRP, Crystle Carter, RN, Donna Catamero, Juliet Escalon, Daniel Verina, Erika Florendo, Moon-hee Yum, RN, Nadege Stevens, RN, Jude Gullie, BA, Elaine Chan, BS, Sundar Jagannath, MD

Blood (2015) 126 (23): 3051.

https://doi.org/10.1182/blood.V126.23.3051.3051

Published: 2015

Journal Articles

A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation

Midori Nakagaki, BPharm, MSc, BCOP, Michael Barras, BPharm, GradDipClinPharm, PhD, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 1910.

https://doi.org/10.1182/blood.V126.23.1910.1910

Published: 2015

Journal Articles

Lower Continuous Infusion, Higher Bolus Dose Patient-Controlled Analgesia Results in Shorter Hospitalization in Children with Sickle Cell Vaso-Occlusive Pain Crisis

Tabetha Todd, PharmD, Jonica Huntman, PharmD, Gianna W. Sparks, Monica L. Hulbert, MD

Blood (2015) 126 (23): 523.

https://doi.org/10.1182/blood.V126.23.523.523

Published: 2015

Journal Articles

A Phase II Study Of Aprepitant As Anti-Emetic Prophylaxis In Patients Receiving Induction Chemotherapy For AML

Joseph Brandwein, MD, FRCPC, Karen W.L. WL Yee, MD, Andre C Schuh, MD, Vikas Gupta, MD, FRCP, FRCPath, Jack T Seki, PharmD

Blood (2013) 122 (21): 5035.

https://doi.org/10.1182/blood.V122.21.5035.5035

Published: 2013

Journal Articles

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

Talha Badar, MBBS, FCPS, Gloria Mattiuzzi, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Guillermo Garcia Manero, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 3887.

https://doi.org/10.1182/blood.V122.21.3887.3887

Published: 2013

Journal Articles

Ofatumumab and Bendamustine in Previously Treated CLL and SLL

Chaitra S. Ujjani, MD, Edmund A Gehan, Pari Ramzi, Catherine Broome, MD, Bruce D. Cheson, MD

Blood (2011) 118 (21): 4615.

https://doi.org/10.1182/blood.V118.21.4615.4615

Published: 2011

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

Impact of 5-Hydroxytryptamine- 3 Receptor Antagonist Step Therapy on Severe Chemotherapy-Induced Nausea and Vomiting Events in Patients with Lymphoma

Hind T Hatoum, PhD, Swu-Jane Lin, PhD, Sanjeev Balu, PhD, MBA

Blood (2011) 118 (21): 3137.

https://doi.org/10.1182/blood.V118.21.3137.3137

Published: 2011

Journal Articles

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

Rebecca Tombleson, Viet Q. Ho, PharmD, BCOP, Eduardo M. Sotomayor, MD, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Javier Pinilla-Ibarz, MD, Lubomir Sokol, MD, PhD, Gene A. Wetzstein, PharmD, BCOP

Blood (2010) 116 (21): 4370.

https://doi.org/10.1182/blood.V116.21.4370.4370

Published: 2010

Journal Articles

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah McCue, PhDP, B. Nebiyou Bekele, PhD, Lianchun Xiao, Gautam Borthakur, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 993.

https://doi.org/10.1182/blood.V114.22.993.993

Published: 2009

Journal Articles

Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.

Patrick Stiff, MD, Mary Fox-Geiman, PharmD, Karen Kiley, MSN, NP, Nancy Porter, MSN, APN, Karen Rychlik, BA, Donna Fletcher-Gonzalez, PharmD, Amir Toor, MD, Scott E. Smith, MD, PhD, Tulio Rodriguez, MD

Blood (2009) 114 (22): 2267.

https://doi.org/10.1182/blood.V114.22.2267.2267

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Novel Therapy for Aggressive Cutaneous T-Cell Lymphoma Leading to Complete Clinical Remission before Allogenic Stem Cell Transplantation

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

a Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells

A Prospective Study of IV Pentamidine for Pneumocystis Jirovecii Pneumonia Prophylaxis in Adult Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplant or Chemotherapy

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation

Lower Continuous Infusion, Higher Bolus Dose Patient-Controlled Analgesia Results in Shorter Hospitalization in Children with Sickle Cell Vaso-Occlusive Pain Crisis

A Phase II Study Of Aprepitant As Anti-Emetic Prophylaxis In Patients Receiving Induction Chemotherapy For AML

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

Ofatumumab and Bendamustine in Previously Treated CLL and SLL

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Impact of 5-Hydroxytryptamine- 3 Receptor Antagonist Step Therapy on Severe Chemotherapy-Induced Nausea and Vomiting Events in Patients with Lymphoma

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only